IDEXX LABORATORIES INC /DE (IDXX) Gross Margin
- Gross margin · 12 months: Value 62.45%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 62.45% | Gross profit / revenue. Period ending 2026-06-30. $2.84B ÷ $4.55B × 100 ≈ 62.45% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 2.84B USD | Gross Profit |
| Revenue | 4.55B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.71B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $2.84B | $4.55B | $1.71B | 62.45% |
| 2026-03-31 | $2.76B | $4.45B | $1.69B | 62.05% |
| 2025-12-31 | $2.66B | $4.30B | $1.64B | 61.80% |
| 2025-09-30 | $2.57B | $4.17B | $1.60B | 61.72% |
| 2025-06-30 | $2.48B | $4.04B | $1.55B | 61.54% |
| 2025-03-31 | $2.41B | $3.93B | (m) | 61.28% |
| 2024-12-31 | $2.38B | $3.90B | $1.52B | 61.04% |
| 2024-09-30 | $2.33B | $3.84B | (m) | 60.72% |
| 2024-06-30 | $2.29B | $3.78B | (m) | 60.41% |
| 2024-03-31 | $2.24B | $3.72B | (m) | 60.14% |
| 2023-12-31 | $2.19B | $3.66B | (m) | 59.82% |
| 2023-09-30 | $2.15B | $3.59B | (m) | 59.89% |
| 2023-06-30 | $2.11B | $3.51B | (m) | 59.97% |
| 2023-03-31 | $2.05B | $3.43B | (m) | 59.71% |
| 2022-12-31 | $2.00B | $3.37B | (m) | 59.52% |
| 2022-09-30 | $1.98B | $3.34B | (m) | 59.16% |
| 2022-06-30 | $1.94B | $3.31B | (m) | 58.70% |
| 2022-03-31 | $1.92B | $3.27B | (m) | 58.56% |
| 2021-12-31 | $1.89B | $3.22B | (m) | 58.76% |
| 2021-09-30 | $1.84B | $3.14B | (m) | 58.77% |
| 2021-06-30 | $1.79B | $3.05B | (m) | 58.83% |
| 2021-03-31 | $1.68B | $2.86B | (m) | 58.86% |
| 2020-12-31 | $1.57B | $2.71B | (m) | 58.04% |
| 2020-09-30 | $1.49B | $2.59B | (m) | 57.61% |
| 2020-06-30 | $1.42B | $2.47B | (m) | 57.18% |
| 2020-03-31 | $1.39B | $2.46B | (m) | 56.71% |
| 2019-12-31 | $1.37B | $2.41B | (m) | 56.73% |
| 2019-09-30 | $1.33B | $2.35B | (m) | 56.78% |
| 2019-06-30 | $1.30B | $2.29B | (m) | 56.55% |
| 2019-03-31 | $1.27B | $2.25B | (m) | 56.41% |
| 2018-12-31 | $1.24B | $2.21B | (m) | 56.10% |
| 2018-09-30 | $1.21B | $2.17B | (m) | 55.93% |
| 2018-06-30 | $1.18B | $2.12B | (m) | 55.85% |
| 2018-03-31 | $1.14B | $2.04B | (m) | 55.87% |
| 2017-12-31 | $1.10B | $1.97B | (m) | 55.73% |
| 2017-09-30 | $1.07B | $1.91B | (m) | 55.91% |
| 2017-06-30 | $1.04B | $1.86B | (m) | 55.75% |
| 2017-03-31 | $1.01B | $1.82B | (m) | 55.28% |
| 2016-12-31 | $975.44M | $1.78B | (m) | 54.94% |
| 2016-09-30 | $952.50M | $1.73B | (m) | 54.99% |
| 2016-06-30 | $930.05M | $1.69B | (m) | 55.03% |
| 2016-03-31 | $902.26M | $1.64B | (m) | 55.12% |
| 2015-12-31 | $890.27M | $1.60B | (m) | 55.58% |
| 2015-09-30 | $854.74M | $1.55B | (m) | 55.00% |
| 2015-06-30 | $843.80M | $1.53B | (m) | 55.10% |
| 2015-03-31 | $829.56M | $1.51B | (m) | 55.01% |
| 2014-12-31 | $816.12M | $1.49B | (m) | 54.93% |
| 2014-09-30 | $822.62M | $1.49B | (m) | 55.29% |
| 2014-06-30 | $795.06M | $1.44B | (m) | 55.11% |
| 2014-03-31 | $774.24M | $1.41B | (m) | 55.10% |
| 2013-12-31 | $756.12M | $1.38B | (m) | 54.91% |
| 2013-09-30 | $736.50M | $1.34B | (m) | 54.86% |
| 2013-06-30 | $721.36M | $1.32B | (m) | 54.66% |
| 2013-03-31 | $708.35M | $1.30B | (m) | 54.37% |
| 2012-12-31 | $699.15M | $1.29B | (m) | 54.06% |
| 2012-09-30 | $688.98M | $1.28B | (m) | 53.78% |
| 2012-06-30 | $677.01M | $1.27B | (m) | 53.46% |
| 2012-03-31 | $666.36M | $1.25B | (m) | 53.36% |
| 2011-12-31 | $646.51M | $1.22B | (m) | 53.05% |
| 2011-09-30 | $632.40M | $1.20B | (m) | 52.91% |
| 2011-06-30 | $615.94M | $1.16B | (m) | 52.92% |
| 2011-03-31 | $591.19M | $1.13B | (m) | 52.43% |
| 2010-12-31 | $578.62M | $1.10B | (m) | 52.44% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $526.28M | $1.03B | (m) | 51.01% |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2008-12-31 | $529.77M | $1.02B | (m) | 51.73% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |